Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Immune Globulin Intravenous (Human), 10% Solution
BIOLOGICAL
2 trials
Sponsors
Baxalta now part of Shire
Conditions
Alzheimer´s Disease
Primary Immunodeficiency Diseases (PID)
Phase 2
Phase 2/3 Study of IGSC, 20% in PIDD
Completed
NCT01218438
Baxalta now part of Shire
Primary Immunodeficiency Diseases (PID)
Start: 2013-01-28
End: 2015-03-13
Updated: 2021-07-20
Phase 3
Phase 3 IGIV, 10% in Alzheimer´s Disease
Terminated
NCT01524887
Baxalta now part of Shire
Alzheimer´s Disease
Start: 2012-01-23
End: 2013-07-16
Updated: 2021-05-19
Related Papers
Pharmacokinetics, safety, and efficacy of 20% subcutaneous immunoglobulin (Ig20Gly) administered weekly or every 2 weeks in Japanese patients with primary immunodeficiency diseases: a phase 3, open-label study
Immunotherapy Advances
2024-01-01
1 citations
Real-World Use, Safety, and Patient Experience of 20% Subcutaneous Immunoglobulin for Primary Immunodeficiency Diseases.
2023-09-26
6 citations
Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real-world study.
2022-08-07
10 citations
Population pharmacokinetic simulation of varied Immune Globulin Subcutaneous (Human), 20% solution (Ig20Gly) loading and maintenance dosing regimens in immunoglobulin-naïve patients with primary immunodeficiency diseases.
2021-10-01
6 citations
Steady-State Serum IgG Trough Levels Are Adequate for Pharmacokinetic Assessment in Patients with Immunodeficiencies Receiving Subcutaneous Immune Globulin.
2021-05-26
3 citations
Tolerability of Ig20Gly during onboarding in patients with primary immunodeficiency diseases.
2019-06-20
4 citations
[P2–004]: THE SAFETY AND EFFICACY OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) FOR ALZHEIMER'S DISEASE: A META‐ANALYSIS
Alzheimer s & Dementia
2017-07-01
2 citations